dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

November 18, 2021: CureVac AG

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty® (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty® were shown to be highly comparable.

Please read the whole article here

CureVac AG, News 2021
November 18, 2021: Cosmo Pharmaceuticals NV
November 18, 2021: CureVac AG

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz